Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...
In a post on X, Kennedy vowed to work to end chronic disease, clean up corruption and provide Americans with the data they ...
Career mobility is one of the best things about working for a large company, especially one with offices across the globe. Diego Moreno, a health economics manager at Novo Nordisk Canada Inc. (NNCI), ...
Halozyme Therapeutics said on Thursday it has proposed to buy German drug developer Evotec for about 2 billion euros ($2.10 billion), to bulk up its drug discovery and development portfolio. Halozyme ...
In the world of health, Novo Nordisk stops insulin pen production, Trump's potential health appointments draw attention, and ...
For the third quarter of 2024, Ascendis Pharma reported a net loss of €99.2 million, or €1.72 per share (basic and diluted) ...
Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...
German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.
The tech company’s prices appear set to undercut the long list of competing telehealth companies that rely on aggressive ...
Courts have long deferred to CMS’s decisions on implementation of laws that govern Medicare. The overturning of the Chevron ...
Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.
Novo Nordisk said Thursday that it plans to eventually halt all of its human insulin pen production globally, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback